Search Results

You are looking at 1 - 10 of 91 items for :

  • "Ovarian carcinoma" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Intraperitoneal Chemotherapy for Ovarian Cancer: Where Are We Now?

Pankaj Singhal and Shashikant Lele

epithelial ovarian carcinoma . Am J Obstet Gynecol 1994 ; 170 : 974 – 979 ; discussion 979–980 . 5. Bristow RE Tomacruz RS Armstrong DK . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era

Full access

CLO20-068: Incidence and Potential Predictors of Thromboembolic Events in Epithelial Ovarian Carcinoma Patients During Perioperative Period

Qingqing Zhou, Chenchen Zhu, Zhen Shen, Jing Zhu, Tianjiao Zhang, Min Li, Jiwei Qin, Lili Qian, Chuan Chen, Hanyuan Liu, Zhihao Xu, Dabao Wu, Björn Nashan, and Ying Zhou

Objective: To assess the incidence and the risk factors of venous thromboembolism (VTE) in patients with epithelial ovarian carcinoma (EOC) during perioperative period. Methods: A retrospective analysis was conducted on the patients with

Full access

Novel Non-Cytotoxic Therapy in Ovarian Cancer: Current Status and Future Prospects

Lainie Martin and Russell J. Schilder

. 20. Nishida N Yano H Komai K . Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma . Cancer 2004 ; 101 : 1364 – 1374 . 21

Full access

Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer

Kari E. Hacker, Shitanshu Uppal, and Carolyn Johnston

borderline ovarian tumors (BOTs) and low-grade epithelial ovarian carcinomas (LG-EOCs) Assess the role of surgery, chemotherapy and fertility/hormonal preservation in the management of BOTs and LG-EOCs The International Federation of Gynecology and

Full access

Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

Research; AO, anaplastic oligodendroglioma; CUP, cancer of unknown primary; ESC, endometrial serious adenocarcinoma; HGSOC, high-grade serous ovarian carcinoma; IBC, invasive breast carcinoma; ICC, intrahepatic cholangiocarcinoma; IDC, invasive ductal

Full access

Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course

Jocelyn S. Chapman, Saurabh Asthana, Lindsay Cade, Matthew T. Chang, Zhen Wang, Charles J. Zaloudek, Stefanie Ueda, Eric A. Collisson, and Barry S. Taylor

to a previously identified BRCA2 germline mutation in a patient diagnosed with an MYC -amplified, TP53 -mutant ovarian carcinoma, who experienced a 32-month complete response to platinum therapy. 10 Moreover, this is a low-incidence variant; only

Full access

Surgery for Ovarian Cancer: Rationale and Guidelines

Benjamin E. Greer, Ron E. Swensen, and Heidi J. Gray

clinically unilateral stage I invasive epithelial ovarian carcinomas . Gynecol Oncol 2001 ; 80 : 56 – 61 . 5 Munoz KA Harlan LC Trimble EL . Patterns of care for women with ovarian cancer in the United States . J Clin Oncol 1997 ; 15 : 3408

Full access

Counterpoint: Intraperitoneal Chemotherapy: An Investigational Treatment in Ovarian Cancer

Robert F. Ozols

-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group. Southwestern Oncology Group, and Eastern Cooperative Oncology Group . J Clin Oncol

Full access

Point: Intraperitoneal Chemotherapy in the Management of Ovarian Cancer

Maurie Markman

mitoxantrone in the management of refractory ovarian carcinoma . J Clin Oncol 1990 ; 8 : 146 – 150 . 25 Berek JS Markman M Stonebraker B . Intraperitoneal interferon-α in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study

Full access

Ovarian Cancer Biomarkers: Current Options and Future Promise

Christine M. Coticchia, Jiang Yang, and Marsha A. Moses

of survival, but no improvement in the cure rate . Eur J Cancer 2002 ; 38 : 2435 – 2445 . 5. Omura GA Brady MF Homesley HD . Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology